- Home
- SCHL vs BCYC Comparison
SCHL vs BCYC Comparison
Compare SCHL & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCHL
- BCYC
- Stock Information
- Founded
- SCHL 1920
- BCYC 2009
- Country
- SCHL United States
- BCYC United Kingdom
- Employees
- SCHL N/A
- BCYC N/A
- Industry
- SCHL Books
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- SCHL Consumer Discretionary
- BCYC Health Care
- Exchange
- SCHL Nasdaq
- BCYC Nasdaq
- Market Cap
- SCHL 501.9M
- BCYC 581.7M
- IPO Year
- SCHL 1987
- BCYC 2019
- Fundamental
- Price
- SCHL $18.97
- BCYC $8.18
- Analyst Decision
- SCHL
- BCYC Buy
- Analyst Count
- SCHL 0
- BCYC 10
- Target Price
- SCHL N/A
- BCYC $25.00
- AVG Volume (30 Days)
- SCHL 338.1K
- BCYC 370.6K
- Earning Date
- SCHL 03-20-2025
- BCYC 05-01-2025
- Dividend Yield
- SCHL 4.20%
- BCYC N/A
- EPS Growth
- SCHL N/A
- BCYC N/A
- EPS
- SCHL 0.65
- BCYC N/A
- Revenue
- SCHL $1,592,100,000.00
- BCYC $25,722,000.00
- Revenue This Year
- SCHL $3.42
- BCYC N/A
- Revenue Next Year
- SCHL $5.47
- BCYC $0.27
- P/E Ratio
- SCHL $29.19
- BCYC N/A
- Revenue Growth
- SCHL N/A
- BCYC N/A
- 52 Week Low
- SCHL $15.77
- BCYC $6.10
- 52 Week High
- SCHL $38.77
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- SCHL 57.78
- BCYC 48.36
- Support Level
- SCHL $18.13
- BCYC $7.95
- Resistance Level
- SCHL $19.13
- BCYC $9.55
- Average True Range (ATR)
- SCHL 0.65
- BCYC 0.73
- MACD
- SCHL 0.28
- BCYC 0.05
- Stochastic Oscillator
- SCHL 88.55
- BCYC 38.84
About SCHL Scholastic Corporation
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.